The clinical pharmacology of the medical treatment for overactive bladder in adults

References

• Link CL, Steers WD, Kusek JW, et al. The association of adiposity and overactive bladder appears to differ by gender: results from the Boston Area Community Health survey. J Urol. 2011;185(3):955–963.
   PubMed Web of Science ®Google Scholar
• Patra PB, Patra S. Sex differences in the physiology and pharmacology of the lower urinary tract. Curr Urol. 2013 Feb;6(4):179–188.
   PubMedGoogle Scholar
• Herschorn S, Kaplan SA, Sun F, et al. Do patient characteristics predict responsiveness to treatment of overactive bladder with antimuscarinic agents? Urology. 2014 May;83(5):1023–1029.
   PubMed Web of Science ®Google Scholar
• Valentini FA, Marti BG, Robain G. Idiopathic and neurogenic detrusor overactivity: do the different patterns have urodynamic characteristics related to gender or neurological condition? Int Braz J Urol. 2013 Sep-Oct;39(5):663–670.
   PubMed Web of Science ®Google Scholar
• Lee UJ, Scott VCS, Rashid R, et al. Defining and managing overactive bladder: disagreement among the experts. Urology. 2013;81(2):257–262.
   PubMed Web of Science ®Google Scholar
• Eapen RS, Radomski SB. Review of the epidemiology of overactive bladder. Res Rep Urol. 2016;8:71–76.
   PubMed Web of Science ®Google Scholar
• Sacco E, Tienforti D, D’Addessi A, et al. Social, economic, and health utility considerations in the treatment of overactive bladder. Open Access J Urol. 2010;2:11.
   PubMedGoogle Scholar
• Haylen BT, De Ridder D, Freeman RM, et al. An international urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodynamics. 2010;29(1):4–20.
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006 Dec;50(6):1306–1314. discussion 1314-5.
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003 May;20(6):327–336.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Vats V, et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011 May;77(5):1081–1087.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Bell JA, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB‐POLL. Neurourol Urodyn. 2013;32(3):230–237.
   PubMed Web of Science ®Google Scholar
• McKellar K, Bellin E, Schoenbaum E, et al. Prevalence, risk factors, and treatment for overactive bladder in a racially diverse population. Urology. 2019 Apr 01;126:70–75.
   PubMed Web of Science ®Google Scholar
• Irwin DE, Abrams P, Milsom I, et al. Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int. 2008 Jun;101(11):1381–1387.
   PubMed Web of Science ®Google Scholar
• Temml C, Heidler S, Ponholzer A, et al. Prevalence of the overactive bladder syndrome by applying the International Continence Society definition. Eur Urol. 2005 Oct;48(4):622–627.
   PubMed Web of Science ®Google Scholar
• Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001 Jun;87(9):760–766.
   PubMed Web of Science ®Google Scholar
• Goldman HB, Anger JT, Esinduy CB, et al. Real-world patterns of care for the overactive bladder syndrome in the United States. Urology. 2016 Jan;87:64–69.
   PubMed Web of Science ®Google Scholar
• Fenner DE, Trowbridge ER, Patel DA, et al. Establishing the prevalence of incontinence study: racial differences in women’s patterns of urinary incontinence. J Urol. 2008 Apr;179(4):1455–1460.
   PubMed Web of Science ®Google Scholar
• Sears CLG, Wright J, O’Brien J, et al. The racial distribution of female pelvic floor disorders in an equal access health care system. J Urol. 2009;181(1):187–192.
   PubMed Web of Science ®Google Scholar
• Dooley Y, Kenton K, Cao G, et al. Urinary incontinence prevalence: results from the national health and nutrition examination survey. J Urol. 2008 Feb;179(2):656–661.
   PubMed Web of Science ®Google Scholar
• Shefchyk SJ. Sacral spinal interneurones and the control of urinary bladder and urethral striated sphincter muscle function. J Physiol. 2001;533(1):57–63.
   PubMed Web of Science ®Google Scholar
• Yoshimura N, Chancellor MB. Neurophysiology of lower urinary tract function and dysfunction. Rev Urol. 2003;5(Suppl 8):S3.
   PubMedGoogle Scholar
• Miller J, Hoffman E. The causes and consequences of overactive bladder. J Women’s Health. 2006;15(3):251–260.
   PubMed Web of Science ®Google Scholar
• Andersson K-E, Pehrson R. CNS involvement in overactive bladder. Drugs. 2003;63(23):2595–2611.
   PubMed Web of Science ®Google Scholar
• Ouslander JG. Management of overactive bladder. N Engl J Med. 2004;350(8):786–799.
   PubMed Web of Science ®Google Scholar
• Fetscher C, Fleichman M, Schmidt M, et al. M3 muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol. 2002;136(5):641–644.
   PubMed Web of Science ®Google Scholar
• Chancellor MB, Yoshimura N. Neurophysiology of stress urinary incontinence. Rev Urol. 2004;6(Suppl 3):S19.
   PubMedGoogle Scholar
• De Groat W. Anatomy and physiology of the lower urinary tract. Urol Clin North Am. 1993;20(3):383.
   PubMed Web of Science ®Google Scholar
• Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci. 2008;9(6):453–466.
   PubMed Web of Science ®Google Scholar
• Aizawa N, Ito H, Sugiyama R, et al. Selective inhibitory effect of imidafenacin and 5-hydroxymethyl tolterodine on capsaicin sensitive C fibers of the primary bladder mechanosensitive afferent nerves in the rat. J Urol. 2015;193(4):1423–1432.
   PubMed Web of Science ®Google Scholar
• Palmer CJ, Choi JM. Pathophysiology of overactive bladder: current understanding. Curr Bladder Dysfunct Rep. 2017;12(1):74–79.
   Web of Science ®Google Scholar
• Peyronnet B, Mironska E, Chapple C, et al. A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. Eur Urol. 2019. DOI:10.1016/j.eururo.2019.02.038.
   Web of Science ®Google Scholar
• Andersson K-E. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3(1):46–53.
   PubMed Web of Science ®Google Scholar
• Suskind AM. The aging overactive bladder: A review of aging-related changes from the brain to the bladder. Curr Bladder Dysfunct Rep. 2017;12(1):42–47.
   PubMed Web of Science ®Google Scholar
• Milsom I, Stewart W, Thüroff J. The prevalence of overactive bladder. Am J Manag Care. 2000;6(11 Suppl):S565–73.
   PubMed Web of Science ®Google Scholar
• Harrison S, Hunnam G, Farman P, et al. Bladder instability and denervation in patients with bladder outflow obstruction. Br J Urol. 1987;60(6):519–522.
   PubMedGoogle Scholar
• Brading AF. A myogenic basis for the overactive bladder. Urology. 1997;50(6):57–67.
   PubMedGoogle Scholar
• Steers WD, De Groat WC. Effect of bladder outlet obstruction on micturition reflex pathways in the rat. J Urol. 1988;140(4):864–871.
   PubMed Web of Science ®Google Scholar
• Banakhar MA, Al-Shaiji TF, Hassouna MM. Pathophysiology of overactive bladder. Int Urogynecol J. 2012;23(8):975–982.
   PubMed Web of Science ®Google Scholar
• Steers WD. Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol. 2002;4(Suppl 4):S7.
   PubMedGoogle Scholar
• Zhu J, Hu X, Dong X, et al. Associations between risk factors and overactive bladder: a meta-analysis. Female Pelvic Med Reconstr Surg. 2019;25(3):238.
   PubMed Web of Science ®Google Scholar
• Kinsey D, Pretorius S, Glover L, et al. The psychological impact of overactive bladder: a systematic review. J Health Psychol. 2016;21(1):69–81.
   PubMed Web of Science ®Google Scholar
• von Gontard A, Vrijens D, Selai C, et al. Are psychological comorbidities important in the aetiology of lower urinary tract dysfunction – ICI‐RS 2018? Neurourol Urodyn. 2019;38:S8–S17.
   PubMed Web of Science ®Google Scholar
• Read KE, Sanger GJ, Ramage AG. Evidence for the involvement of central 5‐HT7 receptors in the micturition reflex in anaesthetized female rats. Br J Pharmacol. 2003;140(1):53–60.
   PubMed Web of Science ®Google Scholar
• Bors E, Turner RD. History and physical examination in neurological urology. J Urol. 1960;83(5):759–767.
   PubMed Web of Science ®Google Scholar
• Drake MJ, Apostolidis A, Cocci A, et al. Neurogenic lower urinary tract dysfunction: clinical management recommendations of the neurologic incontinence committee of the fifth international consultation on incontinence 2013. Neurourol Urodyn. 2016;35(6):657–665.
   PubMed Web of Science ®Google Scholar
• Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6):2455–2463.
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Nishizawa O, Takeda M, et al. Clinical guidelines for overactive bladder. Int J Urol. 2009 Feb;16(2):126–142.
   PubMed Web of Science ®Google Scholar
• Thuroff JW, Abrams P, Andersson KE, et al. EAU guidelines on urinary incontinence. Actas Urologicas Espanolas. 2011 Jul-Aug;35(7):373–388.
   PubMed Web of Science ®Google Scholar
• Lightner DJ, Gomelsky A, Souter L, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202(3):558–563.
   PubMed Web of Science ®Google Scholar
• Burgio KL, Kraus SR, Menefee S, et al. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. Ann Intern Med. 2008;149(3):161–169.
   PubMed Web of Science ®Google Scholar
• Burgio KL. Update on behavioral and physical therapies for incontinence and overactive bladder: the role of pelvic floor muscle training. Curr Urol Rep. 2013;14(5):457–464.
   PubMed Web of Science ®Google Scholar
• Lee H-E, Oh S-J. The effectiveness of bladder training in overactive bladder. Curr Bladder Dysfunct Rep. 2014;9(1):63–70.
   Google Scholar
• Monteiro S, Riccetto C, Araújo A, et al. Efficacy of pelvic floor muscle training in women with overactive bladder syndrome: a systematic review. Int Urogynecol J. 2018;29(11):1565–1573.
   PubMed Web of Science ®Google Scholar
• Wolz-Beck M, Reisenauer C, Kolenic GE, et al. Physiotherapy and behavior therapy for the treatment of overactive bladder syndrome: a prospective cohort study. Arch Gynecol Obstet. 2017;295(5):1211–1217.
   PubMed Web of Science ®Google Scholar
• Andersson K-E, Chapple CR, Cardozo L, et al. Pharmacological treatment of overactive bladder: report from the international consultation on incontinence. Curr Opin Urol. 2009;19(4):380–394.
   PubMed Web of Science ®Google Scholar
• Andersson K-E. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol. 2011;59(3):377–386.
   PubMed Web of Science ®Google Scholar
• Yamaguchi O. Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action. Int J Urol. 2013;20(1):28–39.
   PubMed Web of Science ®Google Scholar
• Epstein BJ, Gums JG, Molina E. Newer agents for the management of overactive bladder. Am Fam Physician. 2006;74:12.
   Web of Science ®Google Scholar
• Wagg AS, Cardozo L, Chapple C, et al. Overactive bladder syndrome in older people. BJU Int. 2007;99(3):502–509.
   PubMed Web of Science ®Google Scholar
• Jirschele K, Sand PK. Oxybutynin: past, present, and future. Int Urogynecol J. 2013;24(4):595–604.
   PubMed Web of Science ®Google Scholar
• Lee HJ, An J, Doo SW, et al. Improvement in spinal cord injury-induced bladder fibrosis using mesenchymal stem cell transplantation into the bladder wall. Cell Transplant. 2015;24(7):1253–1263.
   PubMed Web of Science ®Google Scholar
• Ohtake A, Ukai M, Hatanaka T, et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol. 2004;492(2–3):243–250.
   PubMed Web of Science ®Google Scholar
• Yamanishi T, Kaga K, Fuse M, et al. The role of muscarinic receptor subtypes on carbachol-induced contraction of normal human detrusor and overactive detrusor associated with benign prostatic hyperplasia. J Pharmacol Sci. 2015;128(2):65–70.
   PubMed Web of Science ®Google Scholar
• Yamada S, Ito Y, Nishijima S, et al. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. Pharmacol Ther. 2018 Sep;189:130–148.
   PubMed Web of Science ®Google Scholar
• Brendler CB, Radebaugh LC, Mohler JL. Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol. 1989;141(6):1350–1352.
   PubMed Web of Science ®Google Scholar
• Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol. 1999;161(6):1809–1812.
   PubMed Web of Science ®Google Scholar
• Diokno AC, Appell RA, Sand PK, et al. editors. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clinic Proceedings; Elsevier; 2003. Vol. 78, No. 6, pp. 687-695.
   Google Scholar
• Homma Y, Paick J, Lee JG, et al. Clinical efficacy and tolerability of extended‐release tolterodine and immediate‐release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo‐controlled trial. BJU Int. 2003;92(7):741–747.
   PubMed Web of Science ®Google Scholar
• Gleason DM, Susset J, White C, et al. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Urology. 1999;54(3):420–423.
   PubMed Web of Science ®Google Scholar
• Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstetrics Gynecol. 2000;95(5):718–721.
   PubMed Web of Science ®Google Scholar
• Yarker YE, Goa KL, Fitton A. Oxybutynin. Drugs Aging. 1995;6(3):243–262.
   PubMed Web of Science ®Google Scholar
• Nilvebrant L. The mechanism of action of tolterodine. Rev Contemp Pharmacother. 2000;11:13–27.
   Web of Science ®Google Scholar
• Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder11A complete list of the members of the tolterodine study group is provided in the appendix. Urology. 2001 Mar 01;57(3):414–421.
   PubMed Web of Science ®Google Scholar
• Nilvebrant L, Gillberg PG, Sparf B. Antimuscarinic potency and bladder selectivity of PNU‐200577, a major metabolite of tolterodine. Pharmacol Toxicol. 1997;81(4):169–172.
   PubMedGoogle Scholar
• Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol. 2001 Jun;41(6):636–644.
   PubMed Web of Science ®Google Scholar
• Todorova A, Vonderheid‐Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol. 2001;41(6):636–644.
   PubMed Web of Science ®Google Scholar
• Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol. 2008;54(4):740–764.
   PubMed Web of Science ®Google Scholar
• Malhotra B, Gandelman K, Sachse R, et al. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem. 2009;16(33):4481–4489.
   PubMed Web of Science ®Google Scholar
• Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother. 2008;9(10):1787–1796.
   PubMed Web of Science ®Google Scholar
• Malhotra B, Guan Z, Wood N, et al. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther. 2008;46(11):556–563.
   PubMed Web of Science ®Google Scholar
• Ney P, Pandita RK, Newgreen DT, et al. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int. 2008;101(8):1036–1042.
   PubMed Web of Science ®Google Scholar
• Nitti V, Wiatrak M, Kreitman L, et al. Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial. Proceedings of the 35th Annual International Continence Society (ICS), Montreal, Canada. abstract; 2005 (306).
   Google Scholar
• Wyndaele JJ, Goldfischer ER, Morrow JD, et al. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int J Clin Pract. 2009 Apr;63(4):560–567.
   PubMed Web of Science ®Google Scholar
• Madhuvrata P, Cody JD, Ellis G, et al. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012 Jan;18(1):Cd005429.
   Google Scholar
• Madersbacher H, Mürtz G. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol. 2001;19(5):324–335.
   PubMed Web of Science ®Google Scholar
• Gotoh M, Yokoyama O, Nishizawa O. Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double‐blind, placebo‐controlled trial. Int J Urol. 2011;18(5):365–373.
   PubMed Web of Science ®Google Scholar
• Haruno A. Inhibitory effects of propiverine hydrochloride on the agonist-induced or spontaneous contractions of various isolated muscle preparations. Arzneimittel-Forschung. 1992;42(6):815–817.
   PubMed Web of Science ®Google Scholar
• Jünemann K-P, Hessdörfer E, Unamba-Oparah I, et al. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urol Int. 2006;77(4):334–339.
   PubMed Web of Science ®Google Scholar
• Madersbacher H, Halaska M, Voigt R, et al. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int. 1999;84(6):646–651.
   PubMed Web of Science ®Google Scholar
• Jünemann K-P, Halaska M, Rittstein T, et al. Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. Eur Urol. 2005;48(3):478–482.
   PubMed Web of Science ®Google Scholar
• Alloussi S, Muertz G, Seibold J, et al. editors. Antimuscarinics in children: is its use in children evidence-based? Int Urogynecol J. 2010;21:S419-S420. SPRINGER LONDON LTD 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND.
   Web of Science ®Google Scholar
• Lee KS, Lee HW, Choo MS, et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the ‘Propiverine study on overactive bladder including urgency data’. BJU Int. 2010;105(11):1565–1570.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Kobayashi S, Suzuki M, et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn-Schmiedeberg’s Arch Pharmacol. 2002 Aug;366(2):97–103.
   Google Scholar
• Nishijima S, Sugaya K, Kadekawa K, et al. Synergistic effect by co-administration of tamsulosin and solifenacin on bladder activity in rats. Low Urin Tract Symptoms. 2012 Jan;4(1):3–8.
   PubMed Web of Science ®Google Scholar
• Nagase K, Ito H, Aoki Y, et al. Co‐administration of an α1‐blocker improves the efficacy and safety of antimuscarinic agents in rats with detrusor overactivity. Int J Urol. 2011;18(12):836–843.
   PubMed Web of Science ®Google Scholar
• Abrams P, Swift S. Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. Eur Urol. 2005;48(3):483–487.
   PubMed Web of Science ®Google Scholar
• Cardozo L, Heßdörfer E, Milani R, et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double‐blind, placebo‐controlled, rising‐dose trial. BJU Int. 2008;102(9):1120–1127.
   PubMed Web of Science ®Google Scholar
• Ito Y, Kashiwabara M, Yoshida A, et al. Muscarinic receptor binding in rat bladder urothelium and detrusor muscle by intravesical solifenacin. Biol Pharm Bull. 2016;39(7):1167–1171.
   PubMed Web of Science ®Google Scholar
• Oki T, Maruyama S, Takagi Y, et al. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice. Eur J Pharmacol. 2006;529(1–3):157–163.
   PubMed Web of Science ®Google Scholar
• Wallis R. Darifenacin, a selective muscarinic M3 antagonist. Pharmacol Res. 1995;31:54.
   Google Scholar
• Zinner N. Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder. Expert Opin Pharmacother. 2007;8(4):511–523.
   PubMed Web of Science ®Google Scholar
• Miyamae K, Yoshida M, Murakami S, et al. Pharmacological effects of darifenacin on human isolated urinary bladder. Pharmacology. 2003;69(4):205–211.
   PubMed Web of Science ®Google Scholar
• Napier C, Gupta P. Darifenacin is selective for the human recombinant M3 receptor subtype. Neurourol Urodyn. 2002;21(4):A445.
   Google Scholar
• Andersson K-E. Potential benefits of muscarinic M3 receptor selectivity. Eur Urol Suppl. 2002;1(4):23–28.
   Web of Science ®Google Scholar
• Yamada S, Maruyama S, Takagi Y, et al. In vivo demonstration of M3 muscarinic receptor subtype selectivity of darifenacin in mice. Life Sci. 2006;80(2):127–132.
   PubMed Web of Science ®Google Scholar
• Maruyama S, Oki T, Otsuka A, et al. Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. J Urol. 2006;175(1):365–369.
   PubMed Web of Science ®Google Scholar
• Jha S, Parsons M. Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309–316.
   PubMed Web of Science ®Google Scholar
• Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol. 2006 Aug;50(2):317–326.
   PubMed Web of Science ®Google Scholar
• Nichols D, Colli E, Goka J, et al. Darifenacin demonstrated no adverse effect on cognitive and cardiac function: results from a double-blind, randomised, placebo-controlled study. Neurourol Urodyn. 2001;20:A354.
   Google Scholar
• Foote J, Glavind K, Kay G. Central nervous system (CNS)-related adverse events in patients with overactive bladder (OAB) treated with darifenacin versus tolterodine. BJU Int. 2004;94((Suppl):2.
   PubMedGoogle Scholar
• Steers W, Corcos J, Foote J, et al. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int. 2005 Mar;95(4):580–586.
   PubMed Web of Science ®Google Scholar
• Dwyer P, Kelleher C, Young J, et al. Long‐term benefits of darifenacin treatment for patient quality of life: results from a 2‐year extension study. Neurourol Urodynamics. 2008;27(6):540–547.
   PubMed Web of Science ®Google Scholar
• Chapple C, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int. 2005;95(7):993–1001.
   PubMed Web of Science ®Google Scholar
• Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100(5):987–1006.
   PubMed Web of Science ®Google Scholar
• Staskin DR. Trospium chloride: distinct among other anticholinergic agents available for the treatment of overactive bladder. Urol Clin North Am. 2006 Nov;33(4):465–73, viii.
   PubMed Web of Science ®Google Scholar
• Zellner M, Madersbacher H, Palmtag H, et al. Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial. Clin Ther. 2009 Nov;31(11):2519–2539.
   PubMed Web of Science ®Google Scholar
• Bodeker RH, Madersbacher H, Neumeister C, et al. Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. BMC Urol. 2010 Sep 14;10:15.
   PubMed Web of Science ®Google Scholar
• Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol. 2003;20(6):392–399.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Nishizawa O, Sugaya K, et al. Effects of trospium chloride on the lower urinary tract function. Hinyokika Kiyo Acta Urologica Japonica. 1990;36(9):1047–1051.
   PubMedGoogle Scholar
• Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol. 2004;171(6Part 1):2311–2315.
   PubMedGoogle Scholar
• Cardozo L, Mirone V, Gratzke C, et al. Extended-release trospium chloride 60 mg – a new once-daily medication for the treatment of overactive bladder syndrome. Eur Urol Rev. 2010;5(1):3–6.
   Google Scholar
• Beckmann‐Knopp S, Rietbrock S, Weyhenmeyer R, et al. Inhibitory effects of trospium chloride on cytochrome P450 enzymes in human liver microsomes. Pharmacol Toxicol. 1999;85:299–304.
   PubMedGoogle Scholar
• Rovner ES. Trospium chloride in the management of overactive bladder. Drugs. 2004;64(21):2433–2446.
   PubMed Web of Science ®Google Scholar
• Homma Y, Yamaguchi O, Group IS. A randomized, double‐blind, placebo‐and propiverine‐controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol. 2009;16(5):499–506.
   PubMed Web of Science ®Google Scholar
• Kobayashi F, Yageta Y, Segawa M, et al. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. Arzneimittelforschung. 2007;57(2):92–100.
   PubMed Web of Science ®Google Scholar
• Kobayashi F, Yageta Y, Yamazaki T, et al. Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Arzneimittelforschung. 2007;57(3):147–154.
   PubMed Web of Science ®Google Scholar
• Seki M, Ogoda M, Kuraoka S, et al. Muscarinic receptor binding of imidafenacin in the human bladder mucosa and detrusor and parotid gland. LUTS: Lower Urinary Tract Symptoms. 2011;3(2):64–68.
   PubMed Web of Science ®Google Scholar
• Yamada S, Seki M, Ogoda M, et al. Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder. J Pharmacol Exp Ther. 2011;336(2):365–371.
   PubMed Web of Science ®Google Scholar
• Masuda Y, Kanayama N, Manita S, et al. Development and validation of bioanalytical methods for Imidafenacin (KRP-197/ONO-8025) and its metabolites in human plasma by liquid chromatography–tandem mass spectrometry. J Chromatogr B. 2007;853(1–2):70–79.
   PubMed Web of Science ®Google Scholar
• Ito Y, Kuraoka S, Endo S, et al. Urinary excretion contributes to long-lasting blockade of bladder muscarinic receptors by imidafenacin: effect of bilateral ureteral ligation. J Pharmacol Exp Ther. 2017;360(1):69–74.
   PubMed Web of Science ®Google Scholar
• Huang W, Zong H, Zhou X, et al. Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis. Int Urol Nephrol. 2015;47(3):457–464.
   PubMed Web of Science ®Google Scholar
• Wada N, Watanabe M, Kita M, et al. Effect of imidafenacin on nocturia and sleep disorder in patients with overactive bladder. Urol Int. 2012;89(2):215–221.
   PubMed Web of Science ®Google Scholar
• Franco I, Horowitz M, Grady R, et al. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction. J Urol. 2005;173(1):221–225.
   PubMed Web of Science ®Google Scholar
• Goessl C, Knispel H, Fiedler U, et al. Urodynamic effects of oral oxybutynin chloride in children with myelomeningocele and detrusor hyperreflexia. Urology. 1998;51(1):94–98.
   PubMed Web of Science ®Google Scholar
• Hajebrahimi S, Chapple CR, Pashazadeh F, et al. Management of neurogenic bladder in patients with Parkinson’s disease: A systematic review. Neurourol Urodyn. 2019;38(1):31–62.
   PubMed Web of Science ®Google Scholar
• Stöhrer M, Blok B, Castro-Diaz D, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol. 2009;56(1):81–88.
   PubMed Web of Science ®Google Scholar
• Abrams P, Andersson KE, Apostolidis A, et al. 6th international consultation on incontinence. Recommendations of the international scientific committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence. Neurourol Urodyn. 2018;37(7):2271–2272.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–562.
   PubMed Web of Science ®Google Scholar
• Buser N, Ivic S, Kessler TM, et al. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol. 2012 Dec;62(6):1040–1060.
   PubMed Web of Science ®Google Scholar
• Lucas MG, Bosch RJ, Burkhard FC, et al. EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol. 2012 Dec;62(6):1130-1142.
   PubMed Web of Science ®Google Scholar
• Wagg A, Nitti VW, Kelleher C, et al. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Curr Med Res Opin. 2016;32(4):621–638.
   PubMed Web of Science ®Google Scholar
• Sexton C, Notte S, Maroulis C, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011;65(5):567–585.
   PubMed Web of Science ®Google Scholar
• Benner JS, Nichol MB, Rovner ES, et al. Patient‐reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276–1282.
   PubMed Web of Science ®Google Scholar
• Yeowell G, Smith P, Nazir J, et al. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open. 8(11): e021889. 2018.
   PubMed Web of Science ®Google Scholar
• Yamanishi T, Chapple CR, Yasuda K, et al. Role of β‐adrenoceptor subtypes in mediating relaxation of the pig bladder trigonal muscle in vitro. Neurourol Urodynamics. 2003;22(4):338–342.
   PubMed Web of Science ®Google Scholar
• Andersson K-E, Martin N, Nitti V. Selective β3-adrenoceptor agonists for the treatment of overactive bladder. J Urol. 2013;190(4):1173–1180.
   PubMed Web of Science ®Google Scholar
• Chapple CR β3-agonist therapy: a new advance in the management of overactive bladder? 2012.
   Google Scholar
• Ohlstein EH, von Keitz A, Michel MC. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol. 2012;62(5):834–840.
   PubMed Web of Science ®Google Scholar
• Gras J. Mirabegron for the treatment of overactive bladder. Drugs Today (Barc). 2012;48(1):25–32.
   PubMed Web of Science ®Google Scholar
• Michel MC, Ochodnicky P, Homma Y, et al. beta-adrenoceptor agonist effects in experimental models of bladder dysfunction. Pharmacol Ther. 2011 Jul;131(1):40–49.
   PubMed Web of Science ®Google Scholar
• Kroll P. Pharmacotherapy for pediatric neurogenic bladder. Pediatr Drugs. 2017;19(5):463–478.
   PubMed Web of Science ®Google Scholar
• Alexandre E, Kiguti L, Calmasini F, et al. Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3‐adrenoceptor activation and α1‐adrenoceptor blockade. Br J Pharmacol. 2016;173(3):415–428.
   PubMed Web of Science ®Google Scholar
• Kelleher C, Hakimi Z, Zur R, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 74(3): 324–333. 2018.
   PubMed Web of Science ®Google Scholar
• Wu T, Duan X, Cao CX, et al. The role of mirabegron in overactive bladder: a systematic review and meta-analysis. Urol Int. 2014;93(3):326–337.
   PubMed Web of Science ®Google Scholar
• Nitti V, Chapple C, Walters C, et al. Safety and tolerability of the β3‐adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12‐week randomised phase III trials and of a 1‐year randomised Phase III trial. Int J Clin Pract. 2014;68(8):972–985.
   PubMed Web of Science ®Google Scholar
• Tyagi P, Tyagi V, Chancellor M. Mirabegron: a safety review. Expert Opin Drug Saf. 2011;10(2):287–294.
   PubMed Web of Science ®Google Scholar
• Warren K, Burden H, Abrams P. Mirabegron in overactive bladder patients: efficacy review and update on drug safety. Ther Adv Drug Saf. 2016;7(5):204–216.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Takeda M, Gotoh M, et al. Vibegron, a novel potent and selective beta3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol. 2018 May;73(5):783–790.
   PubMed Web of Science ®Google Scholar
• Di Salvo J, Nagabukuro H, Wickham L, et al. Pharmacological characterization of a novel beta 3 adrenergic agonist, vibegron: evaluation of antimuscarinic receptor selectivity for combination therapy for overactive bladder. J Pharmacol Exp Ther. 2017;360(2):346–355.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Takeda M, Gotoh M, et al. Efficacy of novel β3‐adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: a post‐hoc analysis of a randomized, double‐blind, placebo‐controlled phase 3 study. Int J Urol. 2019;26(3):369–375.
   PubMed Web of Science ®Google Scholar
• Schurch B, Schmid DM, Stöhrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med. 2000;342(9): 665-665. DOI:10.1056/NEJM200003023420918.
   PubMed Web of Science ®Google Scholar
• Smith CP, Boone TB, De Groat WC, et al. Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res Bull. 2003;61(2):165–171.
   PubMed Web of Science ®Google Scholar
• Gajewski JB, Schurch B, Hamid R, et al. An International Continence Society (ICS) report on the terminology for adult neurogenic lower urinary tract dysfunction (ANLUTD). Neurourol Urodyn. 37(3): 1152–1161. 2018.
   PubMed Web of Science ®Google Scholar
• Lin Y-H, Chiang B-J, Liao C-H. Mechanism of action of botulinum toxin A in treatment of functional urological disorders. Toxins (Basel). 2020;12(2):129.
   PubMed Web of Science ®Google Scholar
• Mangera A, Apostolidis A, Andersson KE, et al. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol. 2014;65(5):981–990.
   PubMed Web of Science ®Google Scholar
• Gu H-Y, Song J-K, Zhang W-J, et al. A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages. Oncotarget. 2017;8(52):90338.
   PubMedGoogle Scholar
• Gong -Q-Q, Xu Y-Q, Xu J, et al. Meta-analysis of randomized controlled trials using botulinum toxin A at different dosages for urinary incontinence in patients with overactive bladder. Front Pharmacol. 2020;10:1618.
   PubMed Web of Science ®Google Scholar
• Kosilov KV, Loparev SA, Ivanovskaya MA, et al. Randomized controlled trial of cyclic and continuous therapy with trospium and solifenacin combination for severe overactive bladder in elderly patients with regard to patient compliance. Ther Adv Urol. 2014;6(6):215–223.
   PubMedGoogle Scholar
• Kosilov KV, Loparev SA, Ivanovskaya MA, et al. Comparative effectiveness of combined low-and standard-dose trospium and solifenacin for moderate overactive bladder symptoms in elderly men and women. Urol Int. 2014;93(4):470–473.
   PubMed Web of Science ®Google Scholar
• Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015;67(3):577–588.
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Kakizaki H, Homma Y, et al. Safety and efficacy of mirabegron as ‘add‐on’ therapy in patients with overactive bladder treated with solifenacin: a post‐marketing, open‐label study in Japan (MILAI study). BJU Int. 2015;116(4):612–622.
   PubMed Web of Science ®Google Scholar
• Gratzke C, van Maanen R, Chapple C, et al. Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II). Eur Urol. 2018;74(4):501–509.
   PubMed Web of Science ®Google Scholar
• Chancellor M, Kianifard F, Beamer E, et al. A comparison of the efficacy of darifenacin alone vs. darifenacin plus a behavioural modification programme upon the symptoms of overactive bladder. Int J Clin Pract. 2008;62(4):606–613.
   PubMed Web of Science ®Google Scholar
• Mattiasson A, Blaakaer J, Høye K, et al. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int. 2003;91(1):54–60.
   PubMed Web of Science ®Google Scholar
• Rovner ES, Raymond K, Andruczyk E, et al. Low‐dose desmopressin and tolterodine combination therapy for treating nocturia in women with overactive bladder: a double‐blind, randomized, controlled study. LUTS: Lower Urinary Tract Symptoms. 2018;10(3):221–230.
   PubMed Web of Science ®Google Scholar
• Klutke CG, Burgio KL, Wyman JF, et al. Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication. J Urol. 2009;181(6):2599–2607.
   PubMed Web of Science ®Google Scholar
• Lee S, Chung B, Kim S, et al. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer Prostatic Dis. 2011;14(4):320.
   PubMed Web of Science ®Google Scholar
• Staskin DR. Combination therapy for overactive bladder: who approves? Eur Urol. 2018 Oct;74(4):510–511.
   PubMed Web of Science ®Google Scholar
• Kasman A, Stave C, Elliott CS. Combination therapy in overactive bladder‐untapped research opportunities: a systematic review of the literature. Neurourol Urodyn. 2019;38(8):2083–2092.
   PubMed Web of Science ®Google Scholar
• Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 193(5): 1572–1580. 2015.
   PubMed Web of Science ®Google Scholar